Tempus AI (TEM) announced it has been selected by the Advanced Research Projects Agency for Health, an agency within the U.S. Department of Health and Human Services, to provide testing and contract research organization services in support of the agency’s Advanced Analysis for Precision Cancer Therapy program.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- tempus AI Inc Class A call volume above normal and directionally bullish
- Tempus AI Stock (TEM) Spikes 9%— Should You Buy Now?
- Ambry Genetics announces improved EHR-integrated BC risk assessment solution
- Short Report: Tempus AI short interest reaches record high
- Tempus AI price target raised to $95 from $80 at Guggenheim